Position in ABCL
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$9,584,238
New position
Shares Held
2,746,200
first reported quarter
Ownership
0.896%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ABCL
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$9,549,338
PutShares
2,736,200
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Jefferies Financial Group Inc. holds $677,219,224 across 66 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
1,357,042 | $110,693,915 | |
| 2 | URGN |
UroGen Pharma Ltd.
|
2,199,652 | $80,947,193 | |
| 3 | IMTX |
Immatics N.V.
|
6,506,802 | $65,913,904 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
2,010,534 | $62,849,292 | |
| 5 | CGON |
CG Oncology, Inc.
|
769,947 | $54,704,734 | |
| 6 | ARGX |
Argenx SE
|
45,068 | $41,812,738 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
929,626 | $31,040,212 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
466,258 | $26,679,282 |
All Filings in ABCL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,584,238 | 2,746,200 | Shares | Defined | 2026-05-08 | |
| 2026-03-31 | $9,549,338 | 2,736,200 | Put | Defined | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||